Cargando…

Obeticholic Acid for Primary Biliary Cholangitis

Primary biliary cholangitis (PBC) is a rare autoimmune cholestatic liver disease that may progress to fibrosis and/or cirrhosis. Treatment options are currently limited. The first-line therapy for this disease is the drug ursodeoxycholic acid (UDCA), which has been proven to normalize serum markers...

Descripción completa

Detalles Bibliográficos
Autores principales:	Floreani, Annarosa, Gabbia, Daniela, De Martin, Sara
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9599277/ https://www.ncbi.nlm.nih.gov/pubmed/36289726 http://dx.doi.org/10.3390/biomedicines10102464

Ejemplares similares

Update on the Pharmacological Treatment of Primary Biliary Cholangitis
por: Floreani, Annarosa, et al.
Publicado: (2022)

Obeticholic acid for primary biliary cholangitis
Publicado: (2020)

Real-world experience with obeticholic acid in patients with primary biliary cholangitis
por: D’Amato, Daphne, et al.
Publicado: (2021)

Obeticholic acid is associated with improvements in AST-to-platelet ratio index and GLOBE score in patients with primary biliary cholangitis
por: Harms, Maren H., et al.
Publicado: (2020)

Experimental Pharmacological Agents for the Treatment of Primary Biliary Cholangitis
por: Floreani, Annarosa
Publicado: (2020)

New developments in the treatment of primary biliary cholangitis – role of obeticholic acid
por: Jhaveri, Manan A, et al.
Publicado: (2017)

Real‐World Effectiveness of Obeticholic Acid in Patients with Primary Biliary Cholangitis
por: Roberts, Surain B., et al.
Publicado: (2020)

Impact of Obeticholic acid Exposure on Decompensation and Mortality in Primary Biliary Cholangitis and Cirrhosis
por: John, Binu V., et al.
Publicado: (2021)

A randomized trial of obeticholic acid monotherapy in patients with primary biliary cholangitis
por: Kowdley, Kris V., et al.
Publicado: (2018)

Reduction and stabilization of bilirubin with obeticholic acid treatment in patients with primary biliary cholangitis
por: Parés, Albert, et al.
Publicado: (2020)

Obeticholic acid for the treatment of primary biliary cholangitis in adult patients: clinical utility and patient selection
por: Bowlus, Christopher L
Publicado: (2016)

A randomized, placebo-controlled, phase II study of obeticholic acid for primary sclerosing cholangitis
por: Kowdley, Kris V., et al.
Publicado: (2020)

Predictors of serious adverse events and non‐response in cirrhotic patients with primary biliary cholangitis treated with obeticholic acid
por: De Vincentis, Antonio, et al.
Publicado: (2022)

The efficacy of adalimumab in psoriatic arthritis concomitant to overlapping primary biliary cholangitis and primary sclerosing cholangitis: a case report
por: Del Ross, Teresa, et al.
Publicado: (2016)

Response Rate and Impact on Lipid Profiles of Obeticholic Acid Treatment for Patients with Primary Biliary Cholangitis: A Meta-Analysis
por: Gao, Yuan, et al.
Publicado: (2021)

Combination therapy of obeticholic acid and ursodeoxycholic acid in patients with primary biliary cholangitis who respond incompletely to ursodeoxycholic acid: a systematic review
por: Li, Xuan, et al.
Publicado: (2020)

Autoimmune biliary diseases: primary biliary cholangitis and primary sclerosing cholangitis
por: Sarcognato, Samantha, et al.
Publicado: (2021)

Morning Bright Light Treatment for Sleep-Wake Disturbances in Primary Biliary Cholangitis: A Pilot Study
por: Turco, Matteo, et al.
Publicado: (2018)

Extrahepatic Manifestations of Primary Biliary Cholangitis
por: Chalifoux, Sara L, et al.
Publicado: (2017)

Cholangiocyte senescence in primary sclerosing cholangitis is associated with disease severity and prognosis
por: Cazzagon, Nora, et al.
Publicado: (2021)

Role of ductular reaction and ductular–canalicular junctions in identifying severe primary biliary cholangitis
por: Overi, Diletta, et al.
Publicado: (2022)

Number needed to treat with ursodeoxycholic acid therapy to prevent liver transplantation or death in primary biliary cholangitis
por: Harms, Maren H, et al.
Publicado: (2020)

The Role of Epigenetics in Primary Biliary Cholangitis
por: Gerussi, Alessio, et al.
Publicado: (2022)

Current understanding of primary biliary cholangitis
por: Tanaka, Atsushi
Publicado: (2021)

Risk Stratification in Primary Biliary Cholangitis
por: Martini, Francesco, et al.
Publicado: (2023)

Primary Biliary Cholangitis and Primary Sclerosing Cholangitis: Current Knowledge of Pathogenesis and Therapeutics
por: Park, Ji-Won, et al.
Publicado: (2022)

Evaluation of the United Kingdom‐primary biliary cholangitis and global primary biliary cholangitis group prognostic models for primary biliary cholangitis patients treated with ursodeoxycholic acid in the U.S. population
por: Alomari, Mohammad, et al.
Publicado: (2019)

External validation of the United Kingdom‐primary biliary cholangitis risk scores of patients with primary biliary cholangitis treated with ursodeoxycholic acid
por: Cheung, Angela C., et al.
Publicado: (2018)

Primary Biliary Cholangitis and Bile Acid Farnesoid X Receptor Agonists
por: Abenavoli, Ludovico, et al.
Publicado: (2020)

Osteoporosis in Primary Biliary Cholangitis: Prevalence, Impact and Management Challenges
por: Trivedi, Hirsh D, et al.
Publicado: (2020)

Biomarkers for primary biliary cholangitis: current perspectives
por: Kouroumalis, Elias, et al.
Publicado: (2018)

New treatments/targets for primary biliary cholangitis
por: Corpechot, Christophe, et al.
Publicado: (2019)

Primary biliary cholangitis: Epidemiology, prognosis, and treatment
por: Trivella, Juan, et al.
Publicado: (2023)

Osteoporosis in primary biliary cholangitis
por: Danford, Christopher J, et al.
Publicado: (2018)

Baricitinib and primary biliary cholangitis
por: Gordon, Stuart C., et al.
Publicado: (2021)

NI‐0801, an anti‐chemokine (C‐X‐C motif) ligand 10 antibody, in patients with primary biliary cholangitis and an incomplete response to ursodeoxycholic acid
por: de Graaf, Kathy L., et al.
Publicado: (2018)

Management of Primary Biliary Cholangitis: Current Treatment and Future Perspectives
por: Barba Bernal, Romelia, et al.
Publicado: (2023)

Genetic Contribution to the Pathogenesis of Primary Biliary Cholangitis
por: Joshita, Satoru, et al.
Publicado: (2017)

Overlap Syndrome between Primary Biliary Cholangitis and Primary Sclerosing Cholangitis
por: Sundaram, Sridhar, et al.
Publicado: (2018)

Features of Lipid Metabolism Disorders in Primary Biliary Cholangitis
por: Reshetnyak, Vasiliy I., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_4rpbl7g5aab42t51g4trs7j733